An Analytical Approach to Biosimilar Drug Development
Providing analytical data on the comparison between a biosimilar and the reference product is a primary consideration in the development of biosimilars.
The long-term safety and efficacy of biosimilars are largely based on clinical studies that have already been conducted on the reference biologic, but these studies may not always be sufficient to ensure that the biosimilar can comparably replace the reference product. Having an analytical strategy can provide important clinical data to indicate similarity between a biosimilar and its reference product. BioPharm Internationalspoke with Patricia Hurley, PhD, senior director, Regulatory Consulting, and Duu-Gong Wu, PhD, senior director, CMC/Regulatory Consulting, both at PPD Consulting and Edward Tabler, associate director, PPD Laboratories’ bioanalytical lab, to gain insight into the impact that analytical testing on biosimilars has on their pathway to regulatory approval.
Read this article in BioPharm International's Biopharma Laboratory Best Practices 2018 eBook.
Article Details
BioPharm International
eBook: Biopharma Laboratory Best Practices 2018
Vol. 31
October 2018
Pages: 8–11
Citation
When referring to this article, please cite it as F. Mirasol, "An Analytical Approach to Biosimilar Drug Development," BioPharm International Biopharma Laboratory Best Practices eBook (October 2018).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
